Abstract
Common (surface) epithelial cancer of the ovary is epitomized by metastasis to organs of the abdominal cavity. Proteolytic enzymes, predominately those of the matrix metalloproteinase and plasminogen activator-plasmin systems, have been implicated as mediators of tissue invasion. This review highlights the salient features of ovarian cancer progression, the proteases involved, and experimental approaches of inhibition. Enzyme inhibitors hold promise in the treatment of early-stage and recurrent (following cytoreductive surgery) disease.
Keywords: matrix metalloproteinase, urokinase, kallikrein, ovarian cancer, protease inhibitor
Current Enzyme Inhibition
Title: Proteolytic Enzymes and Their Inhibition in Epithelial Ovarian Cancer
Volume: 1 Issue: 2
Author(s): A. McDonnel Smedts, T. E. Curry Jr. and W. J. Murdoch
Affiliation:
Keywords: matrix metalloproteinase, urokinase, kallikrein, ovarian cancer, protease inhibitor
Abstract: Common (surface) epithelial cancer of the ovary is epitomized by metastasis to organs of the abdominal cavity. Proteolytic enzymes, predominately those of the matrix metalloproteinase and plasminogen activator-plasmin systems, have been implicated as mediators of tissue invasion. This review highlights the salient features of ovarian cancer progression, the proteases involved, and experimental approaches of inhibition. Enzyme inhibitors hold promise in the treatment of early-stage and recurrent (following cytoreductive surgery) disease.
Export Options
About this article
Cite this article as:
Smedts McDonnel A., Curry Jr. E. T. and Murdoch J. W., Proteolytic Enzymes and Their Inhibition in Epithelial Ovarian Cancer, Current Enzyme Inhibition 2005; 1 (2) . https://dx.doi.org/10.2174/1573408054022199
DOI https://dx.doi.org/10.2174/1573408054022199 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Computational Analysis of the Interaction between Ligand-Receptor Pairs
Current Pharmaceutical Design Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Stimuli Responsive Nanoparticles for Controlled Anti-cancer Drug Release
Current Medicinal Chemistry From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Gene Therapy of Cancer with Interleukin-12
Current Pharmaceutical Design The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Prospects of Primary Ovarian Insufficiency Patient-Specific Pluripotent Stem Cells for Disease Modeling and Clinical Impacts
Current Women`s Health Reviews Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Malignant Pleural Mesothelioma in 2011. Is there a Gold Standard Therapy?
Current Respiratory Medicine Reviews ATP Citrate Lyase Inhibitors as Novel Cancer Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Development of Pin1 Inhibitors and their Potential as Therapeutic Agents
Current Medicinal Chemistry Q-TOF LC/MS-based Untargeted Metabolomics Approach to Evaluate the Effect of Folate-Conjugated Cyclodextrins on Triple-Negative Breast Cancer Cells
Current Pharmaceutical Analysis Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Anti-HER2 Therapy in Elderly Breast Cancer Patients
Reviews on Recent Clinical Trials Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design